Small-molecule aggregation inhibitors reduce excess amyloid in a trisomy 16 mouse cortical cell line

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Beta-amyloid peptide aggregation and neurotoxicity are implicated in neurodegenerative diseases.
• Down's syndrome is associated with trisomy 16 in mice, leading to overexpression of amyloid precursor protein (APP) and elevated intracellular calcium.
• Previous research identified small organic compounds that prevent beta-amyloid aggregation and neurotoxicity.

Purpose of the Study:

• To evaluate the effect of previously characterized small molecule organic compounds on amyloid precursor protein (APP) accumulation.
• To assess these compounds in a trisomy 16 mouse-derived cell line (CTb), an animal model for Down's syndrome.

Main Methods:

• Utilized the CTb immortalized cell line, derived from trisomy 16 mouse cerebral cortex, and a control non-trisomic cortical cell line (CNh).
• Measured intracellular APP accumulation and basal intracellular calcium levels ([Ca2+]).
• Administered specific compounds: 2,4-dinitrophenol, 3-nitrophenol, and 4-anisidine.

Main Results:

• CTb cells exhibited higher APP levels and slightly elevated resting intracellular Ca2+ compared to CNh cells.
• 2,4-dinitrophenol, 3-nitrophenol, and 4-anisidine significantly decreased intracellular APP accumulation in CTb cells.
• These compounds were non-toxic to the cells and caused a slight increase in basal intracellular Ca2+.

Conclusions:

• The tested compounds show potential for reducing intracellular vesicular APP accumulation in trisomic cells.
• These findings suggest a therapeutic avenue for conditions involving APP overexpression, such as Down's syndrome.
• Further development of these compounds could lead to novel drug candidates for managing APP-related pathologies.